Traws Pharma
Pre-Approval PRO BETAPipeline by Phase
Therapeutic Focus
Clinical Trials (31)
Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA
Started: 12/2/2015
Randomized Study of ON 01910.Na in Refractory Myelodysplastic Syndrome Patients With Excess Blasts
Started: 11/1/2010
Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine
Started: 8/1/2013
Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer
Started: 5/1/2011
Early-stage Trial to Determine a Safe and Effective Dose for Ratutrelvir in Patients With Mild to Moderate COVID-19
Started: 9/16/2025
Phase 2a Study of the Efficacy and Safety of TRX-100 in a Human Influenza A Challenge Model
Started: 6/1/2026
This is an Early-stage Clinical Trial to Determine a Safe and Effective Dose for Tivoxavir Marboxil in Patients With Mild to Moderate Influenza
Started: 12/15/2025
Oral Rigosertib in Low Risk MDS Patients Refractory to ESAs
Started: 7/1/2013
Effect of 2-h Infusion of ON 01910.Na in Ovarian Cancer Patients
Started: 3/1/2009
Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome
Started: 5/1/2012
Efficacy and Safety of ON 01910.Na in Myelodysplastic Syndrome (MDS) Patients With Trisomy 8 or Classified as Intermediate-1, -2 or High Risk
Started: 5/1/2009
Study of TRX-100 Tablets Evaluating the Safety, Pharmacokinetics, and Food Effect in Healthy Volunteers
Started: 3/25/2026
Evaluation Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of 83-0060 in Healthy Volunteers
Started: 4/15/2024
A Clinical Study Aiming to Assess Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TRX-100 in Healthy Volunteers
Started: 8/13/2024
Dose-escalation, Safety and Pharmacokinetic Study of Briciclib in Advanced Solid Tumors
Started: 6/1/2014
Phase II Part 2 Expansion of Oral Rigosertib in Combination With Azacitidine
Started: 8/1/2013
Three Dosing Schedules of Oral Rigosertib in MDS Patients
Started: 5/1/2014
Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS)
Started: 10/1/2008
Study of 72-Hour Infusion of ON 01910.Na in Patients With MDS or AML
Started: 1/1/2009
Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL)
Started: 7/1/2010
Safety, Pharmacokinetics and Clinical Activity of Oral Rigosertib in Solid Tumors
Started: 7/1/2010
Efficacy and Safety of 5-day Dosing of ON 01910.Na in Intermediate-1,-2, or High Risk Myelodysplastic Syndrome (MDS)
Started: 3/1/2009
Platinum-based Chemoradiotherapy and Rigosertib in Head and Neck Cancer
Started: 1/1/2014
Safety and Pharmacokinetic Study of Oral ON 01910.Na in Patients With Myelodysplastic Syndrome
Started: 12/1/2009
Safety of ON 01910.Na and Irinotecan or ON 01910.Na and Oxaliplatin in Patients With Hepatoma
Started: 6/1/2008
Metabolism and Excretion of [14C]-Rigosertib After Infusion to Volunteers
Started: 1/1/2014
Safety Study of ON 01910.Na in Combination With Irinotecan or Oxaliplatin
Started: 2/1/2008
Dose Escalation Study of Gemcitabine and ON 01910.Na in Solid Tumors
Started: 1/1/2009
Safety of 24-hour Infusion of ON 01910.Na in Combination With Gemcitabine in Advanced Solid Tumors
Started: 1/1/2010
Safety Study of ON 013105 in Lymphoma and Acute Lymphoid Leukemia
Started: 11/1/2009